ADDvise acquires Southern Life Systems, Inc.

24-11-2021   Regulatory press release

ADDvise Group AB has today entered into a share purchase agreement with the owners of Sothern Life Systems, Inc. (“SLS”) regarding the acquisition of all shares of SLS in accordance with the letter of intent communicated via a press release dated August 30, 2021. Closing of the acquisition takes place today.

SLS’ revenue for the year 2020 amounted to approximately USD 11.56 million, with an adjusted EBITDA of approximately USD 1.68 million, equaling an EBITDA margin of 14.5%.

The purchase price amounts to a total of approximately USD 11.00 million, divided into an initial payment of approximately USD 7.60 million on a cash and debt-free basis and two potential earn-outs, given that the seller achieves certain predetermined targets. The potential earn-outs amount to maximum of approximately USD 1.51 million for the fiscal year 2022 and approximately USD 1.90 million for the fiscal year 2023.

The acquisition is financed through own funds. ADDvise assesses that the acquisition will have a positive impact on ADDvise earnings per share.

Advisor

Mangold Fondkommission AB is the financial advisor to ADDvise for the acquisition.

For further information, please contact:

Rikard Akhtarzand, CEO
+46 765-25 90 71

rikard.akhtarzand@addvisegroup.se

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.

Latest press releases

Interim report 2025, January 1–March 31

Regulatory

In the first quarter of 2025, net revenue increased organically with continued good profitability, which shows stable demand in medical technology and laboratory solutions. Cash flow from operating activities was strong, driven by improved working capital while EBITA, the company’s new main profit measure, decreased compared to the same quarter last year. Through increased operational…

Invitation to presentation of interim report January 1 – March 31, 2025

Non-regulatory

ADDvise Group publishes its interim report January 1 – March 31, 2025 on Friday, May 9, 2025 at 7.45 am (CET). Media, investors and analysts are invited to attend a webcast and teleconference on the same day at 14:00 (CET). CEO, Staffan Torstensson, and Interim CFO, Johan Irwe, will present the report. Webcast If you wish…

Notice to the annual general meeting of ADDvise Group AB (publ)

Regulatory

ADDvise Group AB (publ), reg. no. 556363–2115, hereby convenes the annual general meeting on 12 May 2025 at 10:00 CEST at Grev Turegatan 30 in Stockholm. Entrance and registration start at 09.30 CEST. NOTIFICATION Shareholders wishing to attend the annual general meeting must: i)          be registered in the share register kept by Euroclear Sweden AB on the…

ADDvise raises approximately SEK 457 million in the rights issue

Regulatory

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES), AUSTRALIA, CANADA, BELARUS, HONG KONG, JAPAN, NEW ZEALAND AND RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL,…